| [1] |
Cervera R. Antiphospholipid syndrome [J]. Thromb Res, 2017, 151(Suppl 1): S43-S47.
|
| [2] |
Miyakis S,Lockshin MD,Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J]. J Thromb Haemost, 2006, 4(2): 295-306.
|
| [3] |
De Groot PG,De Laat B. Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome [J]. Best Pract Res Clin Rheumatol, 2017, 31(3): 334-341.
|
| [4] |
Bienaimé F,Legendre C,Terzi F, et al. Antiphospholipid syndrome and kidney disease [J]. Kidney Int, 2017, 91(1): 34-44.
|
| [5] |
Pengo V,Bison E,Zoppellaro G, et al. APS - Diagnostics and challenges for the future [J]. Autoimmun Rev, 2016, 15(11): 1031-1033.
|
| [6] |
Schreiber K,Sciascia S,de Groot PG, et al. Antiphospholipid syndrome [J]. Nat Rev Dis Primers, 2018, 4: 17103.
|
| [7] |
Sciascia S,Cuadrado MJ,Khamashta M, et al. Renal involvement in antiphospholipid syndrome [J]. Nat Rev Nephrol, 2014, 10(5): 279-289.
|
| [8] |
Tektonidou MG,Sotsiou F,Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome [J]. Arthritis Rheum, 2004, 50(8): 2569-2579.
|
| [9] |
Mehrani T,Petri M. IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus [J]. J Rheumatol, 2011, 38(3): 450-453.
|
| [10] |
Moroni G,Ventura D,Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis [J]. Am J Kidney Dis, 2004, 43(1): 28-36.
|
| [11] |
Tsuruta Y,Uchida K,Itabashi M, et al. Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis [J]. Intern Med, 2009, 48(21): 1875-1880.
|
| [12] |
Jordan N,Chaib A,Sangle S, et al. Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients [J]. Arthritis Care Res (Hoboken), 2014, 66(5): 725-731.
|
| [13] |
Bhandari S,Harnden P,Brownjohn AM, et al. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis [J]. QJM, 1998, 91(6): 401-409.
|
| [14] |
Pattanashetti N,Anakutti H,Ramachandran R, et al. Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis [J]. Kidney Int Rep, 2017, 2(5): 844-849.
|
| [15] |
Hahn BH,McMahon MA,Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis [J]. Arthritis Care Res (Hoboken), 2012, 64(6): 797-808.
|
| [16] |
Bertsias GK,Tektonidou M,Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis [J]. Ann Rheum Dis, 2012, 71(11): 1771-1782.
|
| [17] |
Soyuöz A,Karadag Ö，Karaagaç T, et al. Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub-phenotypes [J]. Eur J Rheumatol, 2018, 5(1): 32-36.
|
| [18] |
Crowther MA,Ginsberg JS,Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [J]. N Engl J Med, 2003, 349(12): 1133-1138.
|
| [19] |
Cohen H,Hunt BJ,Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial [J]. Lancet Haematol, 2016, 3(9): e426-e436.
|
| [20] |
Yagi S,Nishiyama S,Abe T, et al. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome [J]. BMJ Case Rep, 2019, 12(1): bcr-2018-227663.
|
| [21] |
Islam MA,Alam F,Wong KK，et al. Thrombotic management of antiphospholipid syndrome: towards novel targeted therapies [J]. Curr Vasc Pharmacol, 2017, 15(4): 313-326.
|
| [22] |
Ohnishi N,Fujieda Y,Hisada R，et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome [J]. Rheumatology (Oxford), 2018，[Epub ahead of print]．
|
| [23] |
Wang CR,Liu MF. Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience [J]. Semin Arthritis Rheum, 2016, 46(1): 102-108.
|
| [24] |
Kello N,Khoury LE,Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature [J]. Semin Arthritis Rheum, 2018, [Epub ahead of print]．
|
| [25] |
Unlu O,Erkan D. Catastrophic antiphospholipid syndrome: Candidate therapies for a potentially lethal disease [J]. Annu Rev Med, 2017, 68: 287-296.
|
| [26] |
Leone A,Radin M,Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review [J]. Autoimmun Rev, 2017, 16(5): 469-477.
|
| [27] |
刘维，张迪，吴沅皞. 系统性红斑狼疮的中医证候与用药文献分析[J]．国际中医中药杂志，2015，37(8)：731-734.
|
| [28] |
陈严文. 叶任高教授中西医结合治疗狼疮性肾炎的经验[J]. 中国中西医结合肾病杂志，2003，4(2)：65-66.
|
| [29] |
刘玉宁，邓跃毅，王立红. 陈以平教授治疗狼疮性肾炎的经验[J]. 中国中西医结合肾病杂志，2003，8(4)：437-438.
|
| [30] |
吴佳丽，鲍晓辉，周智林，等．益气活血化瘀法对系统性红斑狼疮血瘀证患者的疗效观察[J]．中国中西医结合肾病杂志，2003，23(11)860-861.
|
| [31] |
王首帆，戴蜀平，徐爱琴，等. 丹参联合激素对狼疮性肾炎患者血清IL-6的影响[J]. 中国实用医药，2013，8(2)：3-4.
|
| [32] |
Lin Y,Yan Y,Zhang H, et al. Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice[J]. Acta Pharm Sin B, 2017, 7(2)：159-166.
|
| [33] |
关明媚，傅君舟，郭群英，等．黄芪与丹参注射液联合治疗狼疮肾炎的临床观察[J]．中国中西医结合杂志，2003，9(4)：529-531.
|